Physician profile
Matthew Ryan Clark
NPI 1194162230
$2,057.58
in general payments reported to CMS, 2019-2025
22 companies · $60.20 in 2025
The $60.20 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $159 · 2021: $318 · 2022: $415 · 2023: $512 · 2024: $98.70 · 2025: $60.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.57 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $448.79 | 2019-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $317.94 | 2019-2025 | Odomzo, Ilumya, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $264.16 | 2022-2023 | Sotyktu |
| Amgen INC. | $179.13 | 2019-2023 | Otezla |
| Lilly USA, LLC | $170.68 | 2019-2023 | Olumiant, Taltz |
| Regeneron Healthcare Solutions, INC. | $119.93 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $85.30 | 2020 | |
| Leo Pharma INC. | $80.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $61.99 | 2023 | |
| Janssen Biotech, INC. | $45.98 | 2021-2022 | |
| Genentech USA, INC. | $39.37 | 2019-2024 | Erivedge |
| Mimedx Group, INC. | $37.35 | 2024-2025 | |
| Incyte Corporation | $33.43 | 2022-2023 | Opzelura |
| Smith+Nephew, INC. | $27.92 | 2022 | |
| Convatec INC. | $24.27 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $23.42 | 2019 | |
| Kerecis Limited | $18.11 | 2022 | |
| Genzyme Corporation | $17.76 | 2020 | |
| Pfizer INC. | $17.47 | 2022 | |
| Arcutis Biotherapeutics, INC. | $15.23 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $14.44 | 2021 | |
| Mayne Pharma Commercial LLC | $14.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.